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Introduction
Increasing access to digital technologies
and proliferation of online social networks
have enabled individuals to become more
active in regulating their personal health
[1,2]. These trends have also facilitated
the formation of communities of indivi-
duals engaged in establishing and pursuing
health research projects [3,4]. The type of
research conducted by these commu-
nities includes self-experimentation, self-
surveillance, analyses of genomic data, and
genome-wide association studies (GWAS)
[5]. These projects are described as
‘‘citizen driven’’ [6], ‘‘participant driven’’
[7], ‘‘crowd sourced’’ [8], or ‘‘participant
centric’’ research [9,10]. What they have
in common is that participants are the
leading force in the initiation or conduct of
research projects. Hence we refer to such
projects as participant-led research (PLR).
Recently, results of several PLR initia-
tives have appeared in high-impact scien-
tific journals [11–13]. In 2011 Nature
Biotechnology published a study of the
effects of lithium on the progression of
amyotrophic lateral sclerosis. This study
arose from self-experimentation by a
group of participants on a website called
patientslikeme.com. Researchers from pa-
tientslikeme.com provided algorithms to
match controls, undertook data analysis,
and wrote up the results for publication
[14]. The findings were subsequently
confirmed by clinical trials. There are
numerous examples of PLR, which differ
by subject matter and methodology. One
example is the ‘‘butter-mind study experi-
ment’’ undertaken by 65 people on Geno-
mera, a web portal for group health studies,
to determine the effects of fat intake on
performance of mathematical calculations
[15]. The study results are available online.
Another example is the 23andMe inVite
study of genetic influences on the response
to treating metastatic breast cancer with
bevacizumab [16].
PLR, whilst potentially a boon to research
[17] and the P4 approach to medicine—
medicine which is personalised, predictive,
preventive, and participatory—poses a num-
ber of challenges [18]. These revolve around
two questions. Can PLR achieve the scientific
rigor needed to complement standard health
research? And, if so, how can it be conducted
ethically? Here, we focus on the latter
question. In particular, on whether adequate
ethical oversight of PLR must involve
standard ethics review.
The principal justification for ethical
oversight in research with humans is
protection of research participants. In
the case of standard research, an institu-
tional review board or ethics review
committee is responsible for assessing a
number of factors, including risk/benefit
ratio, quality of informed consent proce-
dures and materials, competence of
researchers, and compliance with obli-
gations to participants. International
guidelines and national legislation re-
quire investigators to obtain ethics ap-
proval before conducting their studies
[19,20]. Should people engaged in PLR
comply with the standard ethics review
process? People considering involvement
in PLR projects, editors of scientific
journals [21], as well as the public with
whom the PLR movement is seeking to
build credibility, require guidance on
these matters.
Unfortunately, there is no sustained
attempt in the literature to address this
issue [22]. Some attention has been given
to informed consent in PLR, but it is
doubtful that ensuring participants receive
appropriate information is sufficient ethi-
cal oversight [23]. In this paper we
approach the ethical oversight question
by first comparing PLR with standard
research to identify the extent to which
similar ethical concerns are raised. On the
basis of this comparison we make a
proposal for adapting current ethical
oversight standards to address the distinc-
tive concerns raised by PLR.
Caveats
We start with the following caveats:
First, we assume that PLR is, in
principle, capable of achieving the level of
scientific rigor required to warrant publi-
cation of its findings in reputable scientific
journals. This assumption is contestable in
light of the methodological limitations of
PLR, including bias, self-selection, and
problems with self-reporting of symptoms
or phenotypic data [8,24]. Moreover, if a
proposed study fails to meet requisite
scientific standards, it is likely to be ethically
impermissible to pursue it [18].
Second, our concern here is the moral
obligation regarding ethical oversight that
arises in the case of PLR. It is a separate
question to what extent this obligation is
properly made socially enforceable, wheth-
er through law or some other mechanism.
Third, we assume that the standard
model of ethics review is broadly appro-
priate for standard research. Ethics review
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aims to protect research participants from
unreasonable risks, coercion, exploitation,
and unfair distribution of burdens and
benefits. It bears noting, however, that the
existing practice of research ethics review
has been criticized as unduly burdensome,
paternalistic, and capable of costing pa-
tients’ lives [25–27].
Fourth, PLR is a heterogeneous phe-
nomenon and the lines between it and
standard research are often blurred. For
example, the GWAS conducted by 23an-
dMe (a direct-to-consumer genomic pro-
vider with a research arm) were described
as ‘‘participant-driven’’ [5]. However, they
were initiated by 23andMe investigators,
with participants being called upon to
contribute by filling out various surveys.
Participants had a choice whether or not
to fill out a survey, but such ‘‘participant-
driven’’ studies closely resemble those
initiated by investigators.
A Comparison of Participant-
Led with Standard Research
Comparing PLR and standard research
reveals at least six areas that are important
with regard to obligations of ethical
oversight. Figure 1 summarizes these
sources of concern and the ethical consid-
erations they generate.
Institutionalization
Both types of research aim at producing
generalizable health knowledge. The pri-
mary agents in standard research typically
belong to standing institutions, rather than
being members of informal groups of
individuals that come together to pursue
a one-off project. These institutions in-
volve hierarchies of authority, often
backed up by legal or other sanctions,
and may have access to considerable
resources. As a result, institutional agents
generally have a greater capacity to affect
the interests of individuals, e.g., to coerce
them into involvement in research. In
addition, institutional structures may pri-
oritize some institutional goal (e.g., profit-
making, reputation building, etc.) that can
obstruct the pursuit of valuable research
[28,29]. In such cases, a worrying mis-
match may arise between the motives of
the participants (for example, altruism or
interest in contributing to the advance-
ment of knowledge) and the goals of the
researchers, leading to the possibility of
participants being exploited or misled.
Admittedly, some forms of PLR also
exhibit an institutional dimension. For exam-
ple, a for-profit company like 23andMe
clearly counts as an institution, and similar
not-for-profit outfits may also do so. Con-
versely, in forms of PLR that lack a clear
institutional structure, the responsibilities of
participants may be ill-defined, and could
result in failure to integrate ethical consider-
ations into decision making.
State Recognition
The institutions that carry out standard
research are typically recipients of official
state recognition (e.g., universities or
liability limited research companies) and,
often, the beneficiaries of material public
support, (e.g., research grants, tax benefits,
subsidies, etc.). This research enterprise is
accountable to the public, in whose name
recognition and support is given, and a key
concern of such accountability is compli-
ance with ethical standards. The public, in
turn, bears a special responsibility to hold
state-supported and recognized bodies
accountable in this way. Moreover, the
public imprimatur conferred on such
institutions generates a responsibility not
to abuse the trust thereby bestowed. On
the other hand, institutions that have
received state recognition and support
have usually been officially vetted in some
way, e.g., as meeting ethical and other
requirements applicable to operating as a
university. Again, to the extent that the
agents pursuing PLR are state-recognized
and supported, e.g., as legally registered
corporations, the preceding points will
apply to them.
Incentive Structures
Researchers may be motivated not only
by the goal of advancing medical knowl-
edge, but also by profit-making, career-
advancement, impacting policy, etc. This
can create incentives to infringe ethical
requirements applying to research, includ-
ing those governing risk of harm and non-
exploitation. Yet, PLR is hardly free of
incentives to engage in unethical behavior.
For example, some PLR takes place within
a profit-making structure. And there are
also potentially distinctive incentive issues
within PLR. Given that those conducting
the research often hope to benefit person-
ally from its outcome (e.g., in experiment-
ing with an off-label use of a medication),
they may be led to engage in unacceptable
forms of risk-taking, and to pressurizing
others to follow suit.
Bottom-up Approach
Some forms of PLR arise out of a
shared interest among a group of non-
experts, e.g., those who suffer from a rare
disease. By contrast, standard research is
typically driven by the interests and
agenda of the established scientific com-
munity. As a result, PLR is not only
potentially an exercise of personal auton-
omy and empowerment on the part of
those involved, it is also an avenue for
pursuing research into topics that are
overlooked or sidelined by the scientific
establishment. Moreover, the flexibility of
the bottom-up approach can lead to an
accelerated pace of research. Yet, given
how group dynamics may develop, a
concern that arises here is the inappropri-
ate use of peer-pressure to promote
participation in a research project. An
additional source of concern arises when
studies are carried out by individuals who
lack research credentials.
Summary Points
N Online social media and digital technologies have facilitated formation of
communities of individuals engaged in establishing and conducting health
research projects. The results of such participant-led research (PLR) have already
appeared in leading biomedical journals.
N These projects involve research with human participants. Hence, what are the
requirements for ethical oversight? To what extent is standard ethics review
also suitable for PLR?
N A comparison of PLR with standard research reveals six areas that are of
potential relevance to ethical oversight: institutionalization, state recognition
and support, incentive structures, openness, bottom-up approach, and self-
experimentation.
N The distinctive nature of PLR requires adaptation of ethical oversight standards
to the character of such research. These should strike a balance between
protecting interests of research participants and achieving promised benefits of
PLR.
N The appropriate form of ethical oversight for PLR projects depends on which of
three categories they fall into. If they meet the ‘‘institution-plus’’ criterion,
standard ethics review applies. If not, then the appropriate form of oversight
depends on the application of a minimal risk criterion.
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Openness
PLR characteristically exhibits openness
in its workings. Study protocols and design
are accessible to participants, e.g., in
crowd-sourced research. They are often
posted online and are accessible to a wider
community, even if not to absolutely
everyone. Openness facilitates transparen-
cy, which is a general ethical demand on
any social decision-making process affect-
ing others. Despite transparency require-
ments such as audits for publicly recog-
nized and supported institutions, standard
health research is widely considered to
have fallen short of fulfilling its obligation
of transparency to society. A vivid illustra-
tion is the general failure to report
negative results from clinical trials. Even
after the introduction of the clinical trial
registration system, concerns persist about
the selective publication of positive results
and the consequent distorting effects on
the assessment of drug effectiveness and
prescription recommendations [30].
Self-Experimentation
Some forms of PLR involve self-exper-
imentation, e.g., by an intervention study
involving over-the-counter drugs, dietary
supplements, or prescription drugs. Other
forms involve the use of genetic informa-
tion or other personal health data. By
contrast, standard health research seldom
involves self-experimentation on the part
of the investigators. Self-experimentation
has a bearing on the reliability of risk-
benefit analyses. First, researchers may
generally run greater risks of harm when
they are not themselves liable to incur it
[31]. Second, when participants in PLR
have a personal stake in the research
outcome (e.g., terminally ill with no
available treatment), they may be led to
undertake unacceptable risks [32]. Finally,
there is a general difference of principle:
regulation of standard health research
with human participants is primarily based
on a concern not to harm others, whereas
regulation of PLR involving self-experi-
mentation largely reflects paternalistic
considerations—preventing harm to self.
Generally speaking, respect for individual
autonomy means that harm to others is a
more robust basis for founding a moral
obligation than harm to self, especially
where the obligation is socially enforce-
able.
The above comparison reveals that
participants in PLR initiatives may also
be at risk of harm and therefore ethical
oversight ensuring appropriate protections
is needed. However, the differences be-
tween standard health research and PLR
have complex implications for what con-
stitutes appropriate ethical oversight of
PLR. Balancing these considerations is
further complicated by the diverse nature
of PLR. In light of this complexity, it is
unlikely that a single formulation of the
obligation of PLR participants regarding
ethical oversight strikes a uniquely correct
balance of the various considerations.
However, it is still worth searching for a
formulation that is plausible, adapted to
the distinctive character of PLR, capable
of attracting wide consensus, and that can
be operationalized without excessive diffi-
culty. In order to stimulate debate on the
appropriate form of ethical oversight for
PLR, we propose the following approach.
Adapting Ethical Oversight to
Participant-Led Research
We propose that the appropriate form
of ethical oversight for PLR depends on
which of the following three categories any
given project falls into.
Category I
Here we place those forms of PLR that
are subject to the standard form of ethics
review that is also applicable to standard
research. PLR belongs to this category if it
is carried out by agents that satisfy the
‘‘institution-plus’’ criterion, i.e., they are
institutions that are either state-recognized,
even if not state-supported, or are engaged
in profit-making. The ‘‘institution-plus’’
criterion picks out those forms of PLR that
are the same as standard research for the
purposes of ethical oversight, and hence are
subject to identical obligations of oversight,
i.e., standard ethics review.
For those forms of PLR that do not
meet the ‘‘institution-plus’’ criterion, we
propose two further categories. We suggest
a risk-based approach based on applying
the minimal risk criterion, i.e., risks
attached to routine medical and psycho-
logical examination [19]. Such risks in-
clude not only physical harm, but also
psychological and social harm, including
privacy violation. In standard ethics re-
view, the ethics review committee makes
the decision to conduct expedited review
or allow exemption from review, on the
basis of the minimal risk criterion. In the
case of PLR it can be made by the
participants in the project, or a designated
group within the project that focuses on
participant protection.
Category II
If the research involves more than
minimal risk to participants, then some
form of ethics review is required. One
possibility may be the creation of forms of
ethics review that are equivalent to
expedited review. For example, ‘‘citizen
ethicists’’ have been proposed as analo-
gous to citizen scientists. Another proposal
worth considering is an open protocol
review that uses crowd-sourcing for ethics
review [33]. A possible outcome of such
expedited review is a recommendation
that standard ethics review be carried
out. This might be, for example, when
the risk to participants reaches a certain
threshold.
Figure 1. Ethical considerations in PLR (resulting from comparing PLR with standard
research).
doi:10.1371/journal.pmed.1001402.g001
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Category III
If the proposed research involves no
more than a minimal risk then no
additional formal ethics review is morally
required. A well-grounded finding of
minimal risk, although it exempts a PLR
project from formal review, obviously does
not exempt those engaged in it from
exercising the level of ethical oversight
we properly expect of people in day-to-day
life. This includes considering respect for
autonomy, avoiding unjustified risk of
harm, fair distribution of burdens and
benefits, and due respect for the law.
Figure 2 summarizes the proposal sche-
matically.
We believe that this scheme merits
further discussion as one way of striking
an appropriate balance between protect-
ing the interests of research participants
and realizing the distinctive benefits of
PLR. In this way, we might prevent ethics
review becoming a strait-jacket on PLR-
inspired innovation, stifling individual
liberty, and serving as a disincentive to
non-experts who might otherwise make
valuable contributions to medical knowl-
edge. This proposal leaves open the issue
of enforceability, which also requires
further debate.
Conclusion
PLR holds out the alluring prospect of
citizen engagement in the co-production
of knowledge with the scientific commu-
nity [34,35]. But like any form of scientific
research involving human participants it is
subject to ethical as well as scientific
standards of appraisal. The appropriate
standards of ethical oversight for PLR
need to be adapted to its distinctive nature.
This article is a contribution to a much
needed broad-ranging dialogue that en-
gages various stakeholders. Failure to
adequately address this issue, and to
generate consensus on best practice, poses
a threat of harm to participants, risks
undermining the credibility of PLR, and
may eventually provoke a backlash of
over-regulation that deprives us of its
potential benefits.
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